On Dec. 28, We had Doctor Qiuling Shi from MD Anderson Cancer Center visiting the hospital and gave us a lecture about clinic trail for improve the research of clinic drug test in the hospital.
Mr. Wan Shaoping, vice director of technology division, hosted the lecture. 30 doctors and staff from Clinical research and standardized treatment ward GCP office attended this lecture.
Dr. Shi introduced MD Anderson briefly. As the top cancer center of America, MD Anderson have about 100 programs of clinic trail of immunotherapy. Then, She gave the detail of her main research, Patient-Reported Outcome(PRO). Different from traditional assessment of life quality, the PRO is questionnaire focus on patient who have untoward effect. This questionnaire has avoid system error by public test. PRO is now the essential part for clinic drug assessment of FDA.
After the lecture, we had further communication with Dr. Shi to discuss the way of collaboration. Doctors found guidance for research from this seminar and knew about the trend of international clinic research.
Dr. Qiuling Shi, got her Ph.D of epidemiology and health statistics in No.4 military medical university. She had an experiment of working in Social Medical School of Hongkong University in 1998-1999, and finished the post-doctoral research in CDC in 2000-2002. She did the post-doctoral research in MDACC from 2002-2006. After that, she stayed in MDACC. She became the Analysis Advisor of clinic trail for anti-cancer drugs in Bristol-Myers Squibb and Amgen Company in 2015.
